Therefore, we assessed the percentage of tumor-infiltrating lymphocytes (TILs) using CD3, CD4, CD8, and PD-L1 expression within the tumor microenvironment by immunohistochemistry (Figure 4A). The gene discussed is CD274; the disease is neoplasm.